Is Wegovy 1.7mg Equivalent to an Ozempic Dose?

What is Wegovy 1.7mg actually for, and where does it sit on the schedule?

Wegovy's titration schedule exists to give your body time to adjust to semaglutide before reaching a full therapeutic dose. The sequence prescribed by a clinician runs from 0.25mg, stepping up roughly every four weeks through 0.5mg, 1mg, and 1.7mg, before reaching the 2.4mg maintenance dose, or the newer 7.2mg option approved by the MHRA in April 2026. The 1.7mg step is the penultimate rung: most people spend one month there before moving to 2.4mg, assuming it is well tolerated.

That context matters because 1.7mg is a transitional dose. For most patients it is neither the goal nor the endpoint. Clinical trial data from the STEP 1 trial, published in the New England Journal of Medicine, showed average weight loss of around 15% over 68 weeks on 2.4mg semaglutide, and that figure reflects the full titrated course, not time spent at intermediate doses. The 1.7mg step contributes to that outcome by preparing the body for the maintenance dose rather than delivering the full effect on its own.

A handful of people do stay at 1.7mg longer if 2.4mg causes side effects that don't settle. That is a clinical decision made with a prescriber, not a self-directed one. You can read more about how the full Wegovy dose schedule is structured if you want a clearer picture of how each step is intended to work.

Does Ozempic have a dose that matches 1.7mg of Wegovy?

No. Ozempic is available in the UK in 0.25mg, 0.5mg, 1mg, and 2mg strengths. There is no 1.7mg Ozempic dose, and more importantly, even the closest numerical match (1mg or 2mg) is not equivalent to Wegovy 1.7mg in any clinical sense.

The reason is that the two medicines are designed around different endpoints. Ozempic's dosing is calibrated for blood glucose management in type 2 diabetes, and if you want to understand how those increments are structured, the page covering the Ozempic semaglutide dose steps explains how each level is intended to work. Wegovy's schedule is calibrated for appetite regulation and weight reduction in people with obesity or overweight. The MHRA licenses these as distinct products for distinct purposes, and the NHS makes that distinction explicit: Ozempic is a diabetes medicine, and using it for weight loss falls outside its UK licence. The NHS semaglutide medicines page covers both products and their respective indications clearly.

People sometimes ask about dose conversion because they have heard that Ozempic can produce weight loss as a side effect, or because Wegovy has been harder to access at certain times. Both things are true, but they don't make the products interchangeable. If you are on Wegovy and want to understand how 1.7mg compares across brands and routes, the page on Wegovy-to-Ozempic dose conversion sets out the practical detail your prescriber would weigh up.

If Ozempic isn't licensed for weight loss, what is the right route?

In the UK, the two medicines licensed specifically for weight management are Wegovy (semaglutide injection) and Mounjaro (tirzepatide). Wegovy is a GLP-1 receptor agonist; Mounjaro activates both GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine licensed here. Both require a prescription following a clinical assessment, and neither should be started, switched, or stopped without a prescriber reviewing the full picture.

For anyone currently on Ozempic for diabetes who is curious about weight outcomes, that conversation belongs with the prescriber managing their diabetes care. For anyone seeking weight-loss treatment who has been pointed toward Ozempic by a friend or an online forum, the honest answer is that the correct licensed options are Wegovy and Mounjaro, and the right starting point is a clinical assessment to work out which one suits your circumstances.

The question of what happens when you move from 1.7mg to 2.4mg (whether timing, side effects, or what to expect) is one the page on stepping up from Wegovy 1.7mg to 2.4mg covers in detail. It's worth reading before that next dose increase, or before raising the topic with your prescriber. And if you're weighing up treatment options more broadly, an overview of the licensed options available sets out the landscape plainly.

One practical note on timing: if you are mid-titration and your next pen is due around a bank holiday or a month-end payday order, it is worth planning the repeat prescription a few days early so the clinical review and dispatch happen before the gap. A prescriber can advise on the clinical side; the logistics piece is simply worth thinking through in advance. You can also find guidance on how Ozempic injection dosage for weight loss differs from the titration used in Wegovy, which is useful context if you are comparing the two medicines before speaking to a clinician.

For anyone ready to explore whether Wegovy or Mounjaro might be clinically appropriate for them, a free consultation with a prescriber is the place to start. Check your eligibility and a GPhC-registered Independent Prescriber will review your details the same day.